登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BioRxiv，3月17日，A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-18

  • A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein

    M. Gordon Joyce, Rajeshwer S Sankhala, Wei-Hung Chen, Misook Choe, Hongjun Bai, Agnes Hajduczki, Lianying Yan, Spencer L Sterling, Caroline Peterson, Ethan C Green, Clayton Smith, Natalia de Val, Mihret Amare, Paul Scott, Eric D Laing, Christopher C Broder, Morgane Rolland, Nelson L Michael, Kayvon Modjarrad

    doi: https://doi.org/10.1101/2020.03.15.992883

    Abstract

    SARS-CoV-2 is a zoonotic virus that has caused a pandemic of severe respiratory disease—COVID-19—within several months of its initial identification. Comparable to the first SARS-CoV, this coronaviruses surface Spike (S) glycoprotein mediates cell entry via the human ACE-2 receptor, and, thus, is the principal target for the development of vaccines and immunotherapeutics. Molecular information on the SARS-CoV-2 S glycoprotein remains limited. Here we report the crystal structure of the SARS-CoV-2 S receptor-binding-domain (RBD) at a the highest resolution to date, of 1.95 Å. We identified a set of SARS-reactive monoclonal antibodies with cross-reactivity to SARS-CoV-2 RBD and other betacoronavirus S glycoproteins.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.03.15.992883v1
30浏览量
原文链接
相关报告

  • 《BioRxiv，3月14日，A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-15
    • A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV Meng Yuan, Nicholas C. Wu, Xueyong Zhu, Chang-Chun D. Lee, Ray T. Y. So, Huibin Lv, Chris K. P. Mok, Ian A. Wilson doi: https://doi.org/10.1101/2020.03.13.991570 Abstract The outbreak of COVID-19, which is caused by SARS-CoV-2 virus, continues to spread globally, but there is currently very little understanding of the epitopes on the virus. In this study, we have determined the crystal structure of the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein in complex with CR3022, a neutralizing antibody previously isolated from a convalescent SARS patient. CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. Structural modeling further demonstrates that the binding site can only be accessed when at least two RBDs on the trimeric S protein are in the ″up″ conformation. Overall, this study provides structural and molecular insight into the antigenicity of SARS-CoV-2. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    70浏览量
    原文链接

  • 《Cell，3月16日，N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-03-23
    • N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 Matthew McCallum # Anna De Marco # Florian A. Lempp Davide Corti Matteo Samuele Pizzuto David Veesler % Show all authors Show footnotes Published:March 16, 2021DOI:https://doi.org/10.1016/j.cell.2021.03.028 Summary The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little is known about neutralizing Abs binding to epitopes outside the RBD and their contribution to protection. Here, we describe 41 human monoclonal Abs (mAbs) derived from memory B cells, which recognize the SARS-CoV-2 S N-terminal domain (NTD) and show that a subset of them neutralize SARS-CoV-2 ultrapotently. We define an antigenic map of the SARS-CoV-2 NTD and identify a supersite (designated site i) recognized by all known NTD-specific neutralizing mAbs. These mAbs inhibit cell-to-cell fusion, activate effector functions, and protect Syrian hamsters from SARS-CoV-2 challenge, albeit selecting escape mutants in some animals. Indeed, several SARS-CoV-2 variants, including the B.1.1.7, B.1.351 and P1 lineages, harbor frequent mutations within the NTD supersite suggesting ongoing selective pressure and the importance of NTD-specific neutralizing mAbs for protective immunity and vaccine design.
    85浏览量
    原文链接